Precede Biosciences: Funding, Investors & Team (Oct 2026)
Precede Biosciences is revolutionizing precision medicine by redefining the knowledge that can be extracted from a basic blood sample. The company's goal is to enhance the probability of successful drug development while fostering a future where every patient can swiftly receive a personalized diagnosis and treatment that aligns with the specific biology of their ailment.
Precede Biosciences has raised $121M across 2 funding rounds on record, the most recent a Series B of $63.5M announced in Jan 2026.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Precede Biosciences Company Profile and Key Stats
Latest funding round on record: Jan 2026.
Precede Biosciences Funding Rounds
Precede Biosciences raised $57.0M in a Series A announced in Oct 2023.
2.3 years later, a Series B of $63.5M was announced in Jan 2026.
Precede Biosciences Founders and Leadership Team
No contact details are on record for this team yet.
Precede Biosciences Funding Compared to Other Biotechnology Startups
Precede Biosciences' latest round of $63.5M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Precede Biosciences in Biotechnology and Boston
Companies Similar to Precede Biosciences
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Precede Biosciences Funding FAQs
What does Precede Biosciences do?
Precede Biosciences is revolutionizing precision medicine by redefining the knowledge that can be extracted from a basic blood sample. The company's goal is to enhance the probability of successful drug development while fostering a future where every patient can swiftly receive a personalized diagnosis and treatment that aligns with the specific biology of their ailment.
How much funding has Precede Biosciences raised?
Precede Biosciences has raised $121M across 2 rounds on record. The most recent is a Series B of $63.5M announced in Jan 2026.
When did Precede Biosciences last raise funding?
Precede Biosciences' most recent funding round on record is a Series B of $63.5M, announced in Jan 2026.
Who is the CEO of Precede Biosciences?
Rehan Verjee is listed as CEO at Precede Biosciences.
Where is Precede Biosciences headquartered?
Precede Biosciences is based in Boston, Massachusetts, United States.
How many employees does Precede Biosciences have?
Precede Biosciences is in the 11-50 employee band.
How does Precede Biosciences' funding compare to other Biotechnology startups?
Precede Biosciences' latest round of $63.5M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Precede Biosciences Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Precede Biosciences is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.